Vision

OxSonics® aims to provide a drug-class-agnostic solution to the greatest challenge in oncological drug delivery: the inability of therapeutic agents to effectively penetrate solid tumours.

The SonoTran® drug delivery platform is designed for the oncology ward and can be used seamlessly with a broad range of current and future therapeutic agents aimed at treating solid tumours. The technique is equally applicable to already marketed and investigational therapeutic agents through partnerships with oncology drug developers.

SonoTran utilizes a purely mechanical effect, triggered by ultrasound applied non-invasively, to actively transport therapeutics throughout tumours without the need for drug reformulation. The same device not only enhances but also enables mapping of the drug delivery process, confirming that the treatment is being successfully applied to the target tissues in real time.

In summary, our vision is to provide economic, scalable and life-changing treatments for cancer patients world-wide, that cause a step-change in the therapeutic efficacy of anti-cancer agents without the development costs or delays associated with drug reformulation.

sonotrans ultrasound
Team
Dr Colin Story

Dr Colin Story
Chief Executive Officer, Executive Director & Co-Founder

close bio
Dr Colin Story

Dr Colin Story
Chief Executive Officer, Executive Director & Co-Founder

Dr Colin Story brings over 20 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd, where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became Co-Founder, Executive Director and the Chief Executive Officer of OxSonics® Ltd.

Prof. Constantin Coussios

Prof. Constantin Coussios
Chief Technology Officer, Non-Executive Director & Co-Founder

close bio
Prof. Constantin Coussios

Prof. Constantin Coussios
Chief Technology Officer, Non-Executive Director & Co-Founder

Professor Constantin holds BA, MEng, MA and PhD degrees in Engineering from the University of Cambridge, and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, where he serves as the Director of the Institute of Biomedical Engineering. He is the author of over 100 peer-reviewed publications and 16 patents in the fields of drug delivery, acoustic cavitation and therapeutic ultrasound. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009 for contributions to biomedical ultrasound, and received the Society’s Bruce Lindsay award in 2012. Prof. Coussios leads the company’s technical development programmes.

Dr Matthew Frohn

Dr Matthew Frohn
Non-Executive Director

close bio
Dr Matthew Frohn

Dr Matthew Frohn
Non-Executive Director

Dr Matthew Frohn graduated from Oxford Brookes University with a BSc Degree in Cell and Molecular Biology followed by a D.Phil in Biochemistry from Oxford University. He worked on research collaborations with Zeneca, and a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999. He is currently a partner of Longwall Venture Partners where he is particularly involved with its life science investments. He became a Non-Executive Director of OxSonicsTM in November 2013.

Mr George Robinson

Mr George Robinson
Board Member

close bio
Mr George Robinson

Mr George Robinson
Board Member

George Robinson is a partner of Sloane Robinson LLP, an investment management business specialising in global equities which he co-founded in 1993. Prior to that, he worked in Asia for 15 years, initially for John Swire & Sons in Hong Kong, Korea and the Philippines, and then for Asia-based stockbroker WI Carr in Korea, Thailand and Hong Kong where he was Director of Regional Research. Mr Robinson graduated with a BA in Engineering Science from Keble College, Oxford in 1979, and is an honorary fellow of Keble College, Oxford as well as a former member of the Oxford University Endowment Investment Committee.

Mr James Mallinson

Mr James Mallinson
Board Member

close bio
Mr James Mallinson

Mr James Mallinson
Board Member

James joined Oxford University Innovation Ltd (OUI) in April 2003 to manage the University of Oxford’s equity stakes in spinout companies. The University’s portfolio comprises shareholdings c80 spinouts valued at c£90m. Among the many investments he has made and managed notable ones include NaturalMotion (sold to Zynga for c$600m), Oxitec (sold to Intrexon for $160m), Oxford Immunotec (NASDAQ IPO in 2014 raising $64m) and Adaptimmune (NASDAQ IPO in 2015 raising $190m). Prior to OUI, James worked in the private equity group at Abbey National Treasury Services as a member of a small team responsible for commitments of £1.9bn. He has also been a member of the Strategic Advisory Board of funds managed by Advent Venture Partners and Avlar BioVentures. James gained his first degree in Engineering Science at the University of Oxford, following which he trained and worked as a software engineer, initially with Marconi Underwater Systems. He gained an MBA from Cranfield in 1990 and has over 24 years of experience in venture capital as both investor and adviser.

Dr Christian Coviello

Dr Christian Coviello
Engineering Director & Co-Founder

close bio
Dr Christian Coviello

Dr Christian Coviello
Engineering Director & Co-Founder

Dr Christian Coviello has a B.S. Degree from Bucknell University and a Ph.D. from in The Pennsylvania State University both in Electrical Engineering. From 2000 to 2005, he was a research assistant at The Applied Research Lab-PSU in the areas of blind source separation, adaptive beamforming and applications of numerical linear algebra. From 2005 to 2009, he was employed as a senior scientist with SAIC in the Advanced Systems and Technology Division in Arlington, VA. There his work primarily focused on image and signal processing algorithm development applied to various sensor systems, from electro-optical to RF. From 2009 to 2015, he was a post-doctoral research fellow at the University of Oxford where he applied his extensive expertise in array beamforming techniques to the optimization of “Passive Acoustic Mapping” algorithms for real-time mapping of drug delivery, particularly using sparse arrays with low channel counts. In April 2015 he joined OxSonics as Head of Engineering and leads the company’s ultrasound systems development.

Dr Nikolaos Chalkias

Dr Nikolaos Chalkias
Operations Director

close bio
Dr Nikolaos Chalkias

Dr Nikolaos Chalkias
Operations Director

Dr Nikolaos Chalkias has a PhD from Cornell University and a BSc from the Aristotle University of Thessaloniki-Greece in Chemical Engineering. Nikolaos brings over 10 years of commercial experience in product development, IP management, and contract negotiation. His career began in 2007 at Reckitt Benckiser’s R&D Department, initially in Product Development and subsequently in the New Technologies Group sourcing technologies and managing external collaborations. In 2011, he joined Oxford University’s Technology Transfer office, Isis Innovation. At Isis Innovation (now Oxford University Innovation) he successfully completed a range of commercial agreements in Biotechnology, Medical Devices, and Diagnostics. Most notably, he was instrumental in setting up three Oxford University spinouts, attracting in excess of £3.5m investment, recruiting management and negotiating all relevant agreements. Nikolaos joined OxSonics in March 2016.

Dr Cliff Rowe

Dr Cliff Rowe
Associate Director, Development

close bio
Dr Cliff Rowe

Dr Cliff Rowe
Associate Director, Development

Dr Cliff Rowe holds a BSc (hons) in Pharmacology from the University of Liverpool and a PhD in Molecular Toxicology from the University of Aberdeen. Cliff has worked on academic pharmacology and drug safety projects at the Universities of Aberdeen, Manchester and at the MRC Centre for Drug Safety Sciences (University of Liverpool). Cliff was previously Principal Scientist at CN BioInnovations where he managed internal research activities and worked on international multi-centre collaborative projects with partners across Europe and the USA. Cliff joined OxSonics as Principal Scientist in April 2015 to work on in-house development programs and co-development projects with strategic partners.

Dr Dinah Parker

Dr Dinah Parker
Clinical & Regulatory Operations Manager

close bio
Dr Dinah Parker

Dr Dinah Parker
Clinical & Regulatory Operations Manager

Dr Dinah Parker gained an MSci in Chemistry and a PhD in Solid State Chemistry from University College London. She then went on to postdoctoral research positions at CEA Saclay, Université Pierre et Marie Curie and the University of Oxford, where her main topics of research were magnetic nanoparticles and novel high temperature superconductors. In 2010, she left academia to join Oxford Instruments Nanoscience where she worked for 6 years in a technical sales role. Dinah joined OxSonics in 2016 as Clinical & Regulatory Operations Manager to implement and manage the company’s clinical, quality and regulatory activities.

Prof. Robert Carlisle

Prof. Robert Carlisle
Oncology Director & Co-Founder

close bio
Prof. Robert Carlisle

Prof. Robert Carlisle
Oncology Director & Co-Founder

Professor Robert Carlisle is the Head of the Drug and Vaccine Delivery Group within the institute of Biomedical Engineering, University of Oxford. After completing a BSc degree in Biochemistry, an MSc in Toxicology and a PhD in Gene Delivery at Birmingham University, he worked for 8 years within the Department of Clinical Pharmacology and the Department of Oncology at the University of Oxford. The majority of his work has been concerned with achieving systemic delivery of anti-cancer agents for the treatment of metastatic cancer. As a consultant to OxSonics, he leads oncology, toxicology and pharmacology.

Prof. Fergus Gleeson FRCP FRCR

Prof. Fergus Gleeson FRCP FRCR

close bio
Prof. Fergus Gleeson FRCP FRCR

Prof. Fergus Gleeson FRCP FRCR

Professor Fergus Gleeson is a Consultant Radiologist and Professor of Radiology in Oxford. He trained in Cambridge, Papworth and London, and was a Fellow in Radiology at UCLA in Los Angeles. He was appointed to Oxford in 1992, and is head of academic radiology, the director of the Oxford Imaging Trials Unit, and a Divisional Director for the Oxford University Hospitals NHS Trust. He advises OxSonics on the clinical administration of ultrasound with regards to patient care, use and usability, and technical performance.

Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

close bio
Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

Hardev Pandha  is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London.  He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006. His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.

The Team

Dr Colin StoryDr Colin Story
Chief Executive Officer, Executive Director & Co-Founder

arrow right Read biography

Dr Colin Story brings over 20 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd, where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became Co-Founder, Executive Director and the Chief Executive Officer of OxSonics® Ltd.

Prof. Constantin CoussiosProf. Constantin Coussios
Chief Technology Officer, Non-Executive Director & Co-Founder

arrow right Read biography

Professor Constantin holds BA, MEng, MA and PhD degrees in Engineering from the University of Cambridge, and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, where he serves as the Director of the Institute of Biomedical Engineering. He is the author of over 100 peer-reviewed publications and 16 patents in the fields of drug delivery, acoustic cavitation and therapeutic ultrasound. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009 for contributions to biomedical ultrasound, and received the Society’s Bruce Lindsay award in 2012. Prof. Coussios leads the company’s technical development programmes.

Dr Matthew FrohnDr Matthew Frohn
Non-Executive Director

arrow right Read biography

Dr Matthew Frohn graduated from Oxford Brookes University with a BSc Degree in Cell and Molecular Biology followed by a D.Phil in Biochemistry from Oxford University. He worked on research collaborations with Zeneca, and a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999. He is currently a partner of Longwall Venture Partners where he is particularly involved with its life science investments. He became a Non-Executive Director of OxSonicsTM in November 2013.

Mr George RobinsonMr George Robinson
Board Member

arrow right Read biography

George Robinson is a partner of Sloane Robinson LLP, an investment management business specialising in global equities which he co-founded in 1993. Prior to that, he worked in Asia for 15 years, initially for John Swire & Sons in Hong Kong, Korea and the Philippines, and then for Asia-based stockbroker WI Carr in Korea, Thailand and Hong Kong where he was Director of Regional Research. Mr Robinson graduated with a BA in Engineering Science from Keble College, Oxford in 1979, and is an honorary fellow of Keble College, Oxford as well as a former member of the Oxford University Endowment Investment Committee.

Mr James MallinsonMr James Mallinson
Board Member

arrow right Read biography

James joined Oxford University Innovation Ltd (OUI) in April 2003 to manage the University of Oxford’s equity stakes in spinout companies. The University’s portfolio comprises shareholdings c80 spinouts valued at c£90m. Among the many investments he has made and managed notable ones include NaturalMotion (sold to Zynga for c$600m), Oxitec (sold to Intrexon for $160m), Oxford Immunotec (NASDAQ IPO in 2014 raising $64m) and Adaptimmune (NASDAQ IPO in 2015 raising $190m). Prior to OUI, James worked in the private equity group at Abbey National Treasury Services as a member of a small team responsible for commitments of £1.9bn. He has also been a member of the Strategic Advisory Board of funds managed by Advent Venture Partners and Avlar BioVentures. James gained his first degree in Engineering Science at the University of Oxford, following which he trained and worked as a software engineer, initially with Marconi Underwater Systems. He gained an MBA from Cranfield in 1990 and has over 24 years of experience in venture capital as both investor and adviser.

Dr Christian CovielloDr Christian Coviello
Engineering Director & Co-Founder

arrow right Read biography

Dr Christian Coviello has a B.S. Degree from Bucknell University and a Ph.D. from in The Pennsylvania State University both in Electrical Engineering. From 2000 to 2005, he was a research assistant at The Applied Research Lab-PSU in the areas of blind source separation, adaptive beamforming and applications of numerical linear algebra. From 2005 to 2009, he was employed as a senior scientist with SAIC in the Advanced Systems and Technology Division in Arlington, VA. There his work primarily focused on image and signal processing algorithm development applied to various sensor systems, from electro-optical to RF. From 2009 to 2015, he was a post-doctoral research fellow at the University of Oxford where he applied his extensive expertise in array beamforming techniques to the optimization of “Passive Acoustic Mapping” algorithms for real-time mapping of drug delivery, particularly using sparse arrays with low channel counts. In April 2015 he joined OxSonics as Head of Engineering and leads the company’s ultrasound systems development.

Dr Nikolaos ChalkiasDr Nikolaos Chalkias
Operations Director

arrow right Read biography

Dr Nikolaos Chalkias has a PhD from Cornell University and a BSc from the Aristotle University of Thessaloniki-Greece in Chemical Engineering. Nikolaos brings over 10 years of commercial experience in product development, IP management, and contract negotiation. His career began in 2007 at Reckitt Benckiser’s R&D Department, initially in Product Development and subsequently in the New Technologies Group sourcing technologies and managing external collaborations. In 2011, he joined Oxford University’s Technology Transfer office, Isis Innovation. At Isis Innovation (now Oxford University Innovation) he successfully completed a range of commercial agreements in Biotechnology, Medical Devices, and Diagnostics. Most notably, he was instrumental in setting up three Oxford University spinouts, attracting in excess of £3.5m investment, recruiting management and negotiating all relevant agreements. Nikolaos joined OxSonics in March 2016.

Dr Cliff RoweDr Cliff Rowe
Associate Director, Development

arrow right Read biography

Dr Cliff Rowe holds a BSc (hons) in Pharmacology from the University of Liverpool and a PhD in Molecular Toxicology from the University of Aberdeen. Cliff has worked on academic pharmacology and drug safety projects at the Universities of Aberdeen, Manchester and at the MRC Centre for Drug Safety Sciences (University of Liverpool). Cliff was previously Principal Scientist at CN BioInnovations where he managed internal research activities and worked on international multi-centre collaborative projects with partners across Europe and the USA. Cliff joined OxSonics as Principal Scientist in April 2015 to work on in-house development programs and co-development projects with strategic partners.

Dr Dinah ParkerDr Dinah Parker
Clinical & Regulatory Operations Manager

arrow right Read biography

Dr Dinah Parker gained an MSci in Chemistry and a PhD in Solid State Chemistry from University College London. She then went on to postdoctoral research positions at CEA Saclay, Université Pierre et Marie Curie and the University of Oxford, where her main topics of research were magnetic nanoparticles and novel high temperature superconductors. In 2010, she left academia to join Oxford Instruments Nanoscience where she worked for 6 years in a technical sales role. Dinah joined OxSonics in 2016 as Clinical & Regulatory Operations Manager to implement and manage the company’s clinical, quality and regulatory activities.

Prof. Robert CarlisleProf. Robert Carlisle
Oncology Director & Co-Founder

arrow right Read biography

Professor Robert Carlisle is the Head of the Drug and Vaccine Delivery Group within the institute of Biomedical Engineering, University of Oxford. After completing a BSc degree in Biochemistry, an MSc in Toxicology and a PhD in Gene Delivery at Birmingham University, he worked for 8 years within the Department of Clinical Pharmacology and the Department of Oncology at the University of Oxford. The majority of his work has been concerned with achieving systemic delivery of anti-cancer agents for the treatment of metastatic cancer. As a consultant to OxSonics, he leads oncology, toxicology and pharmacology.

Prof. Fergus Gleeson FRCP FRCRProf. Fergus Gleeson FRCP FRCR

arrow right Read biography

Professor Fergus Gleeson is a Consultant Radiologist and Professor of Radiology in Oxford. He trained in Cambridge, Papworth and London, and was a Fellow in Radiology at UCLA in Los Angeles. He was appointed to Oxford in 1992, and is head of academic radiology, the director of the Oxford Imaging Trials Unit, and a Divisional Director for the Oxford University Hospitals NHS Trust. He advises OxSonics on the clinical administration of ultrasound with regards to patient care, use and usability, and technical performance.

Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)Prof. Hardev Pandha  MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

arrow right Read biography

Hardev Pandha  is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London.  He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006. His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.

History

OxSonics® technology is built on more than ten years of peer-reviewed research and development within the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford, an internationally recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.

The founding team combines extensive multi-disciplinary commercial, scientific and translational expertise. Dr Colin Story has more than 19 years’ life sciences industrial experience in roles spanning project management, marketing, licensing, operations, fundraising and corporate finance. Prof. Constantin Coussios is a world expert in acoustic cavitation, ultrasound-mediated drug delivery and early-phase clinical trials. Prof. Robert Carlisle’s expertise spans oncology, virology and toxicology. Dr Christian Coviello has extensive experience in array and systems design across the biomedical and defence sectors. 

 

ultrasound scanner
© OxSonics Ltd 2017